MedTrace Logo

Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis

NCT02068482 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2014-02-21

No results posted yet for this study

Summary

Diverticulosis of the colon is a frequent condition in adults in western countries and a significant number of patients experience clinical symptoms even when the diverticulosis is not complicated by diverticulitis.

Both central and mucosal immunity are altered in Uncomplicated Symptomatic Diverticular Disease (USDD) and Rifaximin ameliorate clinical symptoms and normalize the immunological abnormalities.

The Study Protocol is verify the modifications in the immunological pattern induced by reducing bacteria related activation of immunity by Rifaximin treatment.

Conditions

  • Diverticular Disease

Interventions

DRUG

Rifaximin

Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months

Sponsors & Collaborators

  • Catholic University of the Sacred Heart

    lead OTHER

Principal Investigators

  • Franco Pandolfi, Professor · CU Sacred Heart

  • Lucio Petruzziello, Doctor · CU Sacred Heart

  • Paola Cesaro, Doctor · CU Sacred Heart

  • Rossella Cianci, Doctor · CU Sacred Heart

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-05-31
Completion
2012-08-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02068482 on ClinicalTrials.gov